NVSNovartis PharmaceuticalsRunning, no new patients
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Early Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 5,101 (final count)
- Started
- Dec 7, 2018
- Main results expected
- May 29, 2030
- Fully finished
- May 29, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Disease-Free Survival (iDFS)
Measured over: Up to approximately 139 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03701334 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC